Complete remission of hairy cell leukemia variant (HCL-v) complicated by red cell aplasia post treatment with rituximab.

Abstract	Hairy cell leukemia variant (HCL-v) is a rare form of a chronic B-cell lymphoproliferative disorder. Unlike typical hairy cell leukemia (HCL) where the complete response (CR) rate to 2-chlorodeoxyadenosine and 2'-deoxycoformycin can approach about 90%, in HCL-v CR is rare and partial response (PR) occurs in approximately 50% with these agents. Rituximab treatment in relapsed or refractory HCL results in a CR of 13% to 53%, but its use in HCL-v has not been reported in the literature to our knowledge. We describe a patient with HCL-v, whose course was previously complicated by pure red cell aplasia who achieved CR after treatment with rituximab. We also briefly review outcomes of treatments used in HCL-v reported in the current literature.
Authors	Hang Quach, Henry Januszewicz, David Westerman
Journal	Haematologica (Haematologica) Vol. 90 Suppl Pg. ECR26 (Nov 2005) ISSN: 1592-8721 [Electronic] Italy
PMID	16266917 (Publication Type: Case Reports, Journal Article)
Chemical References	Antibodies, Monoclonal Antibodies, Monoclonal, Murine-Derived Antineoplastic Agents Deoxyadenosines Interferon-alpha 2-Chloroadenosine Rituximab Cyclophosphamide Prednisolone 2-chloro-3'-deoxyadenosine
Topics	2-Chloroadenosine (administration & dosage, analogs & derivatives) Aged Antibodies, Monoclonal (therapeutic use) Antibodies, Monoclonal, Murine-Derived Antineoplastic Agents (therapeutic use) Antineoplastic Combined Chemotherapy Protocols (therapeutic use) Blood Transfusion Combined Modality Therapy Cyclophosphamide (administration & dosage) Deoxyadenosines (administration & dosage) Disease Progression Drug Resistance, Neoplasm Fatal Outcome Humans Interferon-alpha (administration & dosage) Leukemia, Hairy Cell (classification, complications, drug therapy, surgery) Male Neoplasms, Second Primary (classification, complications, drug therapy) Prednisolone (administration & dosage) Recurrence Red-Cell Aplasia, Pure (drug therapy, etiology) Remission Induction Rituximab Splenectomy Urinary Bladder Neoplasms (radiotherapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!